These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 7850780

  • 1. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study.
    Cohn SL, Look AT, Joshi VV, Holbrook T, Salwen H, Chagnovich D, Chesler L, Rowe ST, Valentine MB, Komuro H.
    Cancer Res; 1995 Feb 15; 55(4):721-6. PubMed ID: 7850780
    [Abstract] [Full Text] [Related]

  • 2. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
    Martinsson T, Sjöberg RM, Hedborg F, Kogner P.
    Cancer Res; 1995 Dec 01; 55(23):5681-6. PubMed ID: 7585654
    [Abstract] [Full Text] [Related]

  • 3. Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma.
    Cohn SL, Rademaker AW, Salwen HR, Franklin WA, Gonzales-Crussi F, Rosen ST, Bauer KD.
    Am J Pathol; 1990 May 01; 136(5):1043-52. PubMed ID: 2349963
    [Abstract] [Full Text] [Related]

  • 4. Combined analysis of DNA ploidy index and N-myc genomic content in neuroblastoma.
    Bourhis J, De Vathaire F, Wilson GD, Hartmann O, Terrier-Lacombe MJ, Boccon-Gibod L, McNally NJ, Lemerle J, Riou G, Bénard J.
    Cancer Res; 1991 Jan 01; 51(1):33-6. PubMed ID: 1988094
    [Abstract] [Full Text] [Related]

  • 5. Trk mRNA and low affinity nerve growth factor receptor mRNA expression and triploid DNA content in favorable neuroblastoma tumors.
    Kogner P, Barbany G, Björk O, Castello MA, Donfrancesco A, Falkmer UG, Hedborg F, Kouvidou H, Persson H, Raschella G.
    Prog Clin Biol Res; 1994 Jan 01; 385():137-45. PubMed ID: 7972205
    [Abstract] [Full Text] [Related]

  • 6. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification.
    Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nuñez G.
    Am J Pathol; 1993 Dec 01; 143(6):1543-50. PubMed ID: 8256847
    [Abstract] [Full Text] [Related]

  • 7. Prolonged N-myc protein half-life in a neuroblastoma cell line lacking N-myc amplification.
    Cohn SL, Salwen H, Quasney MW, Ikegaki N, Cowan JM, Herst CV, Kennett RH, Rosen ST, DiGiuseppe JA, Brodeur GM.
    Oncogene; 1990 Dec 01; 5(12):1821-7. PubMed ID: 2284101
    [Abstract] [Full Text] [Related]

  • 8. TrkA expression in peripheral neuroblastic tumors: prognostic significance and biological relevance.
    Shimada H, Nakagawa A, Peters J, Wang H, Wakamatsu PK, Lukens JN, Matthay KK, Siegel SE, Seeger RC.
    Cancer; 2004 Oct 15; 101(8):1873-81. PubMed ID: 15386308
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.
    Nakagawara A, Kadomatsu K, Sato S, Kohno K, Takano H, Akazawa K, Nose Y, Kuwano M.
    Cancer Res; 1990 May 15; 50(10):3043-7. PubMed ID: 2185879
    [Abstract] [Full Text] [Related]

  • 11. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H, van Sluis P, de Kraker J, Bökkerink J, Egeler M, Laureys G, Slater R, Westerveld A, Voûte PA, Versteeg R.
    N Engl J Med; 1996 Jan 25; 334(4):225-30. PubMed ID: 8531999
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. N-myc amplification and cell proliferation rate in human neuroblastoma.
    Pession A, Trerè D, Perri P, Rondelli R, Montanaro L, Mantovani W, Derenzini M, Paolucci G.
    J Pathol; 1997 Nov 25; 183(3):339-44. PubMed ID: 9422991
    [Abstract] [Full Text] [Related]

  • 14. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
    Brinkschmidt C, Christiansen H, Terpe HJ, Simon R, Lampert F, Boecker W, Dockhorn-Dworniczak B.
    Med Pediatr Oncol; 2001 Jan 25; 36(1):11-3. PubMed ID: 11464859
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
    Bown N, Cotterill S, Lastowska M, O'Neill S, Pearson AD, Plantaz D, Meddeb M, Danglot G, Brinkschmidt C, Christiansen H, Laureys G, Speleman F, Nicholson J, Bernheim A, Betts DR, Vandesompele J, Van Roy N.
    N Engl J Med; 1999 Jun 24; 340(25):1954-61. PubMed ID: 10379019
    [Abstract] [Full Text] [Related]

  • 18. Loss of one HuD allele on chromosome #1p selects for amplification of the N-myc proto-oncogene in human neuroblastoma cells.
    Grandinetti KB, Spengler BA, Biedler JL, Ross RA.
    Oncogene; 2006 Feb 02; 25(5):706-12. PubMed ID: 16278682
    [Abstract] [Full Text] [Related]

  • 19. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE, London WB, Cohn SL, Maris JM, Kretschmar C, Diller L, Brodeur GM, Castleberry RP, Look AT.
    J Clin Oncol; 2005 Sep 20; 23(27):6466-73. PubMed ID: 16116152
    [Abstract] [Full Text] [Related]

  • 20. Amplification of N-myc as a prognostic marker for patients with neuroblastoma.
    Schwab M.
    Semin Cancer Biol; 1993 Feb 20; 4(1):13-8. PubMed ID: 8448374
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.